PLX — Protalix BioTherapeutics Share News
0.000.00%
Last trade - 00:00- $205.46m
- $164.80m
- $52.74m
Israel's Protalix Q1 revenue surges on Chiesi milestone
Brief: Protalix BioTherapeutics Q1 EPS USD 0.23
Brief: Protalix Biotherapeutics Reports Fiscal Year 2025 Financial And Business Results
Brief: EU Approves Four‑week Dosing Option For Chiesi and Protalix’s Elfabrio
Brief: Protalix Biotherapeutics And Secarna Pharmaceuticals Enter Into Collaboration And Option Agreement
Protalix BioTherapeutics Q3 revenue, profit drop on varying client purchase patterns
Brief: Chiesi Global Rare Diseases Seeks Ema Chmp Re-Exam Of Negative View On Elfabrio 2 Mg/Kg Q4w Dosing
Brief: Chiesi Global Rare Diseases And Protalix Biotherapeutics Seek Re-Examination From The EMA For The Negative Opinion For Elfabrio (Pegunigalsidase Alfa) Alternative Dosing Regimen Of Every Four Weeks In The EU
Brief: Eyal Rubin Resigns As CFO Of Protalix Biotherapeutics - SEC Filing
Brief: Protalix BioTherapeutics Q2 net income USD -2.203 million
Brief: Protalix Biotherapeutics Reports Third Quarter 2023 Financial And Business Results
US-listed healthcare stocks fall amid Middle East conflict
Brief: Protalix Biotherapeutics Issues Statement Regarding Security Situation In Israel
US-listed healthcare firms down amid Middle East conflict
Brief: Protalix Biotherapeutics Appoints Eliot Richard Forster, Ph.D. As Chairman Of Its Board Of Directors
Protalix to get $20 mln milestone payment, shares rise
Brief: Protalix Biotherapeutics Announces $20 Million Payment From Chiesi Global Rare Diseases
Brief: Protalix Biotherapeutics And Partner Chiesi Global Rare Diseases And Announce FDA Approval Of Genetic Disorder Therapy
Protalix jumps on FDA nod for genetic disorder therapy